NCT06914778Recruiting
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Source: ClinicalTrials.gov · Last updated 10 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light into a nerve impulse. This leads to damage and blindness via various different mechanisms that are not fully understood. In this study the objective is to recruit people with diabetes and various stages of diabetic eye disease and measure a large number of different chemicals within the blood that might be associated with damage and dysfunction within the retina. Additionally, it will examine the different bacteria within the gut that might affect disease in the eye via chemicals circulating in the blood. This will require participants to have blood samples taken and to provide urine samples. The blood will be analysed with specialised instruments to identify specific molecules circulating within the blood. Participants will also need to allow researchers to look at their medical records, previous photographs and specialist scans of the back of the eye to grade their diabetic retinopathy. This will allow us to identify potential ways in which these could be targeted for future benefit for people with diabetes to hopefully prevent deterioration of their vision.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 31 Mar 2025
- Start date
- 31 Mar 2025
- Primary completion date
- 1 Jan 2030
- Lead sponsor
- Hywel Dda Health Board
- Diseases
- Type 2 diabetes, Diabetic eye disease
- NCT number
- NCT06914778
What you commit to
- Study type: Observational
- Planned participants: 120
- From 31 Mar 2025 to the primary completion date, 1 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with intravitreal therapies for DMO
Other illness
- Potential participant with a known infective disease that may put the study team at risk (eg. TB, HIV, hepatitis)
- Known underlying genetic condition affecting lipid metabolism
Age
- Age 17 yo or less or 81 yo or older
Other
- Participant unable or unwilling to consent to inclusion in the study
Who the study is looking for
- Diagnosis of type 2 diabetes mellitus
- Male or female aged 18 - 80 inclusive
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prince Philip Hospital Coordinator of this site? Confirm its status | Llanelli | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.